Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells

A. L. Asher, J. J. Mulé, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The role of an immune response in recombinant-human-tumor-necrosis-factor(rHTNF)-mediated regression of a weakly immunogenic, MCA-106 sarcoma in vivo was examined. C57BL/6 mice bearing established 10-day s.c. tumor were treated with single i.v. doses (8 μg) of rHTNF. rHTNF administration resulted in marked hemorrhagic necrosis and subsequent regression of tumor in treated mice. Mice cured of MCA-106 sarcoma by rHTNF specifically rejected a subsequent challenge (5×105 cells) of the same tumor (P+ cells, but not of L3T4+ cells. The in vivo role of T-cell subsets in rHTNF-mediated tumor regression is discussed.

Original languageEnglish (US)
Pages (from-to)153-156
Number of pages4
JournalCancer Immunology Immunotherapy
Volume28
Issue number2
DOIs
StatePublished - Feb 1989
Externally publishedYes

Fingerprint

Sarcoma
Neoplasms
T-Lymphocyte Subsets
Inbred C57BL Mouse
Necrosis
human TNF protein

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells. / Asher, A. L.; Mulé, J. J.; Rosenberg, S. A.

In: Cancer Immunology Immunotherapy, Vol. 28, No. 2, 02.1989, p. 153-156.

Research output: Contribution to journalArticle

Asher, A. L. ; Mulé, J. J. ; Rosenberg, S. A. / Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells. In: Cancer Immunology Immunotherapy. 1989 ; Vol. 28, No. 2. pp. 153-156.
@article{7d5760d7a18c4dca9c14369fb89cab20,
title = "Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells",
abstract = "The role of an immune response in recombinant-human-tumor-necrosis-factor(rHTNF)-mediated regression of a weakly immunogenic, MCA-106 sarcoma in vivo was examined. C57BL/6 mice bearing established 10-day s.c. tumor were treated with single i.v. doses (8 μg) of rHTNF. rHTNF administration resulted in marked hemorrhagic necrosis and subsequent regression of tumor in treated mice. Mice cured of MCA-106 sarcoma by rHTNF specifically rejected a subsequent challenge (5×105 cells) of the same tumor (P+ cells, but not of L3T4+ cells. The in vivo role of T-cell subsets in rHTNF-mediated tumor regression is discussed.",
author = "Asher, {A. L.} and Mul{\'e}, {J. J.} and Rosenberg, {S. A.}",
year = "1989",
month = "2",
doi = "10.1007/BF00199117",
language = "English (US)",
volume = "28",
pages = "153--156",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells

AU - Asher, A. L.

AU - Mulé, J. J.

AU - Rosenberg, S. A.

PY - 1989/2

Y1 - 1989/2

N2 - The role of an immune response in recombinant-human-tumor-necrosis-factor(rHTNF)-mediated regression of a weakly immunogenic, MCA-106 sarcoma in vivo was examined. C57BL/6 mice bearing established 10-day s.c. tumor were treated with single i.v. doses (8 μg) of rHTNF. rHTNF administration resulted in marked hemorrhagic necrosis and subsequent regression of tumor in treated mice. Mice cured of MCA-106 sarcoma by rHTNF specifically rejected a subsequent challenge (5×105 cells) of the same tumor (P+ cells, but not of L3T4+ cells. The in vivo role of T-cell subsets in rHTNF-mediated tumor regression is discussed.

AB - The role of an immune response in recombinant-human-tumor-necrosis-factor(rHTNF)-mediated regression of a weakly immunogenic, MCA-106 sarcoma in vivo was examined. C57BL/6 mice bearing established 10-day s.c. tumor were treated with single i.v. doses (8 μg) of rHTNF. rHTNF administration resulted in marked hemorrhagic necrosis and subsequent regression of tumor in treated mice. Mice cured of MCA-106 sarcoma by rHTNF specifically rejected a subsequent challenge (5×105 cells) of the same tumor (P+ cells, but not of L3T4+ cells. The in vivo role of T-cell subsets in rHTNF-mediated tumor regression is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0024586089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024586089&partnerID=8YFLogxK

U2 - 10.1007/BF00199117

DO - 10.1007/BF00199117

M3 - Article

C2 - 2783890

AN - SCOPUS:0024586089

VL - 28

SP - 153

EP - 156

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -